The methodology of calculation of sample size in “non-inferiority” comparative controlled clinical trials: a comparison of two proportions in parallel group

The absolute majority of clinical trials of generic drugs aimed to compare the therapeutic efficacy of the tested drug and the drug of an active control. It is necessary to estimate that the test drug is not less effective (or non-inferior) than the control drug. The designs of the aforementioned tr...

Full description

Bibliographic Details
Main Authors: A. A. Lyashenko, M. S. Svishcheva
Format: Article
Language:Russian
Published: Izdatelstvo OKI 2018-06-01
Series:Качественная клиническая практика
Subjects:
Online Access:https://www.clinvest.ru/jour/article/view/369
_version_ 1797262081376911360
author A. A. Lyashenko
M. S. Svishcheva
author_facet A. A. Lyashenko
M. S. Svishcheva
author_sort A. A. Lyashenko
collection DOAJ
description The absolute majority of clinical trials of generic drugs aimed to compare the therapeutic efficacy of the tested drug and the drug of an active control. It is necessary to estimate that the test drug is not less effective (or non-inferior) than the control drug. The designs of the aforementioned trials are called “non-inferiority” study; often, these are phase III of clinical trials. The primary criterions of effectiveness which are quite often used in the clinical trials are frequencies of signs, as a result of the analysis of binary data. Binary data are analyzed by comparing proportions. One of the most important conditions for a correct interpretation of the data obtained during the clinical trials — to provide necessary and suffi cient sample size. The purpose of this article is to show how to plan the study, how to provide necessary and sufficient sample size to ensure that the results and conclusions would be reliable; how to interpret the data in a comparative controlled study aimed to establish “non­inferiority” using proportions comparing in parallel groups.
first_indexed 2024-04-24T23:51:26Z
format Article
id doaj.art-fd5b0f7e39a8421ca76701a27ff937c1
institution Directory Open Access Journal
issn 2588-0519
2618-8473
language Russian
last_indexed 2024-04-24T23:51:26Z
publishDate 2018-06-01
publisher Izdatelstvo OKI
record_format Article
series Качественная клиническая практика
spelling doaj.art-fd5b0f7e39a8421ca76701a27ff937c12024-03-14T18:09:07ZrusIzdatelstvo OKIКачественная клиническая практика2588-05192618-84732018-06-01032428373The methodology of calculation of sample size in “non-inferiority” comparative controlled clinical trials: a comparison of two proportions in parallel groupA. A. Lyashenko0M. S. Svishcheva1Первый МГМУ им И.М. Сеченова, НИИ молекулярной медицины, г. МоскваООО «Центр медицинских биотехнологий», г. МоскваThe absolute majority of clinical trials of generic drugs aimed to compare the therapeutic efficacy of the tested drug and the drug of an active control. It is necessary to estimate that the test drug is not less effective (or non-inferior) than the control drug. The designs of the aforementioned trials are called “non-inferiority” study; often, these are phase III of clinical trials. The primary criterions of effectiveness which are quite often used in the clinical trials are frequencies of signs, as a result of the analysis of binary data. Binary data are analyzed by comparing proportions. One of the most important conditions for a correct interpretation of the data obtained during the clinical trials — to provide necessary and suffi cient sample size. The purpose of this article is to show how to plan the study, how to provide necessary and sufficient sample size to ensure that the results and conclusions would be reliable; how to interpret the data in a comparative controlled study aimed to establish “non­inferiority” using proportions comparing in parallel groups.https://www.clinvest.ru/jour/article/view/369клинические исследованияисследования неменьшей эффективностиграница неменьшей эффективностисравнитель­ные контролируемые исследования в параллельных группахдоверительный интервалформула подсчёта выборкисравнение пропорций
spellingShingle A. A. Lyashenko
M. S. Svishcheva
The methodology of calculation of sample size in “non-inferiority” comparative controlled clinical trials: a comparison of two proportions in parallel group
Качественная клиническая практика
клинические исследования
исследования неменьшей эффективности
граница неменьшей эффективности
сравнитель­ные контролируемые исследования в параллельных группах
доверительный интервал
формула подсчёта выборки
сравнение пропорций
title The methodology of calculation of sample size in “non-inferiority” comparative controlled clinical trials: a comparison of two proportions in parallel group
title_full The methodology of calculation of sample size in “non-inferiority” comparative controlled clinical trials: a comparison of two proportions in parallel group
title_fullStr The methodology of calculation of sample size in “non-inferiority” comparative controlled clinical trials: a comparison of two proportions in parallel group
title_full_unstemmed The methodology of calculation of sample size in “non-inferiority” comparative controlled clinical trials: a comparison of two proportions in parallel group
title_short The methodology of calculation of sample size in “non-inferiority” comparative controlled clinical trials: a comparison of two proportions in parallel group
title_sort methodology of calculation of sample size in non inferiority comparative controlled clinical trials a comparison of two proportions in parallel group
topic клинические исследования
исследования неменьшей эффективности
граница неменьшей эффективности
сравнитель­ные контролируемые исследования в параллельных группах
доверительный интервал
формула подсчёта выборки
сравнение пропорций
url https://www.clinvest.ru/jour/article/view/369
work_keys_str_mv AT aalyashenko themethodologyofcalculationofsamplesizeinnoninferioritycomparativecontrolledclinicaltrialsacomparisonoftwoproportionsinparallelgroup
AT mssvishcheva themethodologyofcalculationofsamplesizeinnoninferioritycomparativecontrolledclinicaltrialsacomparisonoftwoproportionsinparallelgroup
AT aalyashenko methodologyofcalculationofsamplesizeinnoninferioritycomparativecontrolledclinicaltrialsacomparisonoftwoproportionsinparallelgroup
AT mssvishcheva methodologyofcalculationofsamplesizeinnoninferioritycomparativecontrolledclinicaltrialsacomparisonoftwoproportionsinparallelgroup